Page last updated: 2024-08-16

resveratrol and plx4032

resveratrol has been researched along with plx4032 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Doi, K; Luo, H; Morisaki, T; Shirasawa, S; Tsunoda, T; Umebayashi, M	1
Bachelot, L; Bessede, A; Boussemart, L; Corre, S; Denison, MS; Dumontet, E; Galibert, MD; Gautron, A; Gilot, D; Guillemin, GJ; Leclair, HM; Marine, JC; Mouchet, N; Perrot, A; Rambow, F; Rogiers, A; Soshilov, A; Tardif, N; Tarte, K	1

Other Studies

2 other study(ies) available for resveratrol and plx4032

Article	Year
Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells. Anticancer research, 2016, Volume: 36, Issue:7 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Melanoma; Mutation, Missense; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Resveratrol; Stilbenes; Sulfonamides; Tumor Cells, Cultured; Vemurafenib	2016
Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nature communications, 2018, 11-14, Volume: 9, Issue:1 Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imidazoles; MCF-7 Cells; Melanoma; Mice; Mice, SCID; Molecular Docking Simulation; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptors, Aryl Hydrocarbon; Resveratrol; Skin Neoplasms; Transcription Factors; Tumor Burden; Vemurafenib; Xenograft Model Antitumor Assays	2018

Article

Year

Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.

Anticancer research, 2016, Volume: 36, Issue:7

Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Inhibitory Concentration 50; Melanoma; Mutation, Missense; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Resveratrol; Stilbenes; Sulfonamides; Tumor Cells, Cultured; Vemurafenib

2016

Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma.

Nature communications, 2018, 11-14, Volume: 9, Issue:1

Topics: Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imidazoles; MCF-7 Cells; Melanoma; Mice; Mice, SCID; Molecular Docking Simulation; Mutation; Oximes; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptors, Aryl Hydrocarbon; Resveratrol; Skin Neoplasms; Transcription Factors; Tumor Burden; Vemurafenib; Xenograft Model Antitumor Assays

2018